This Project Grant award from the Defense Health Agency provides $1,077,570.00 to New York University (NYU) to develop a state-of-the-art microbur-driven non-absorbable epithelial SERT antagonist to treat anxiety and depression in military members and the general public. The award is funded under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public through innovative research.
NYU, a leading research university, will leverage its expertise in areas like infectious disease diagnostics and Alzheimer's disease research to advance this new therapy for mental health conditions. The project will run from September 1, 2023 to August 31, 2026. This award is part of NYU's extensive portfolio of federal grant and contract work across diverse domains, including cybersecurity, transportation, and environmental neuroscience, involving collaborations with partners like DARPA, NIH, and the Department of Veterans Affairs.
Generated 5/7/24, 6:26 AM